Jun 26, 2026 07:01AM
Jun 26, 2026 07:00AM
May 18, 2026 07:01AM
May 18, 2026 07:00AM
May 13, 2026 07:00AM
May 13, 2026 07:00AM
Apr 30, 2026 08:31AM Can-Fite reports phase 2a pancreatic cancer data for namodenoson
Apr 30, 2026 08:31AM
Mar 26, 2026 09:28AM
Mar 26, 2026 09:27AM
Mar 17, 2026 07:47AM
Mar 17, 2026 07:47AM
Mar 4, 2026 10:26AM
Mar 4, 2026 10:25AM Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
Mar 4, 2026 07:02AM
Dec 23, 2025 04:47PM
Dec 23, 2025 04:46PM
Dec 16, 2025 09:19AM
Dec 16, 2025 09:19AM
Nov 26, 2025 07:01AM
Nov 26, 2025 07:00AM Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
Jul 30, 2025 07:04AM
Jul 30, 2025 07:04AM
Jul 28, 2025 12:24PM
Jul 28, 2025 12:24PM
Apr 14, 2025 02:29PM
Apr 14, 2025 02:28PM
Apr 14, 2025 08:01AM Can-Fite BioPharma (CANF) Reports 2024 Financial Results and Clinical Update
Apr 14, 2025 08:00AM
Mar 24, 2025 09:00AM
Feb 18, 2025 07:00AM
Feb 10, 2025 07:10AM
Feb 5, 2025 07:00AM
Jan 27, 2025 07:00AM
Nov 12, 2024 07:51AM H.C. Wainwright Reiterates Buy Rating on Can-Fite BioPharma (CANF)
Nov 4, 2024 07:12AM
Nov 4, 2024 07:08AM
Oct 18, 2024 09:11AM
Oct 18, 2024 09:06AM
Oct 7, 2024 07:00AM
Sep 16, 2024 07:00AM
Aug 29, 2024 08:17AM Can-Fite BioPharma (CANF) Reports H1, Provides Updates on Two Pivotal Phase III Studies
Aug 29, 2024 08:15AM
Jul 17, 2024 07:00AM
Jun 28, 2024 07:00AM
Jun 28, 2024 07:00AM
Jun 24, 2024 07:00AM
Jun 24, 2024 07:00AM
Jun 10, 2024 07:00AM Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study
Jun 5, 2024 07:03AM

325,547 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All